Evolva Holding SA
EvoNext Holdings SA is in the process of liquidation of its remaining assets. Previously, the company was engaged in discovery, research, development, and commercialization of nature-based ingredients for use in flavor and fragrances, health ingredients, health protection, and other sectors in Switzerland, the United States, and internationally. The company was formerly known as Evolva Holding SA… Read more
Evolva Holding SA (ELVAF) - Net Assets
Latest net assets as of December 2024: $6.60 Million USD
Based on the latest financial reports, Evolva Holding SA (ELVAF) has net assets worth $6.60 Million USD as of December 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($7.54 Million) and total liabilities ($945.30K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.60 Million |
| % of Total Assets | 87.47% |
| Annual Growth Rate | -14.55% |
| 5-Year Change | -95.45% |
| 10-Year Change | -96.76% |
| Growth Volatility | 64.0 |
Evolva Holding SA - Net Assets Trend (2005–2024)
This chart illustrates how Evolva Holding SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Evolva Holding SA (2005–2024)
The table below shows the annual net assets of Evolva Holding SA from 2005 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $6.60 Million | +18.80% |
| 2023-12-31 | $5.55 Million | -94.77% |
| 2022-12-31 | $106.24 Million | -19.38% |
| 2021-12-31 | $131.77 Million | -9.18% |
| 2020-12-31 | $145.09 Million | -15.92% |
| 2019-12-31 | $172.56 Million | -11.12% |
| 2018-12-31 | $194.16 Million | -12.03% |
| 2017-12-31 | $220.72 Million | +27.54% |
| 2016-12-31 | $173.06 Million | -14.92% |
| 2015-12-31 | $203.42 Million | +16.24% |
| 2014-12-31 | $174.99 Million | +110.12% |
| 2013-12-31 | $83.28 Million | +35.99% |
| 2012-12-31 | $61.24 Million | -16.36% |
| 2011-12-31 | $73.22 Million | +38.23% |
| 2010-12-31 | $52.97 Million | -22.03% |
| 2009-12-31 | $67.93 Million | +210.74% |
| 2008-12-31 | $21.86 Million | -67.43% |
| 2007-12-31 | $67.12 Million | +2.51% |
| 2006-12-31 | $65.48 Million | -49.97% |
| 2005-12-31 | $130.88 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Evolva Holding SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 36899722000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.23 Million | 109.62% |
| Other Components | $474.58 Million | 7194.57% |
| Total Equity | $6.60 Million | 100.00% |
Evolva Holding SA Competitors by Market Cap
The table below lists competitors of Evolva Holding SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ni Hsin Resources Bhd
KLSE:7215
|
$4.82 Million |
|
Itama Ranoraya
JK:IRRA
|
$4.82 Million |
|
Biotron Limited
PINK:BITRF
|
$4.82 Million |
|
Refined Metals Corp.
PINK:RFMCF
|
$4.82 Million |
|
Titanium Sands Ltd
AU:TSL
|
$4.82 Million |
|
Scandium Canada Ltd
PINK:SCDCF
|
$4.82 Million |
|
Pangenomic Health Inc.
F:LL3
|
$4.82 Million |
|
KT Medical Service PCL
BK:KTMS
|
$4.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Evolva Holding SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 5,552,600 to 6,596,300, a change of 1,043,700 (18.8%).
- Net income of 1,044,000 contributed positively to equity growth.
- Other comprehensive income decreased equity by 100.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $1.04 Million | +15.83% |
| Other Comprehensive Income | $-100.00 | -0.0% |
| Other Changes | $-200.00 | -0.0% |
| Total Change | $- | 18.80% |
Book Value vs Market Value Analysis
This analysis compares Evolva Holding SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.98x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.00x to 0.98x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-12-31 | $1774.38 | $0.90 | x |
| 2006-12-31 | $775.76 | $0.90 | x |
| 2007-12-31 | $699.51 | $0.90 | x |
| 2008-12-31 | $194.31 | $0.90 | x |
| 2009-12-31 | $199.03 | $0.90 | x |
| 2010-12-31 | $73.50 | $0.90 | x |
| 2011-12-31 | $91.73 | $0.90 | x |
| 2012-12-31 | $69.78 | $0.90 | x |
| 2013-12-31 | $88.68 | $0.90 | x |
| 2014-12-31 | $124.32 | $0.90 | x |
| 2015-12-31 | $119.65 | $0.90 | x |
| 2016-12-31 | $89.97 | $0.90 | x |
| 2017-12-31 | $114.48 | $0.90 | x |
| 2018-12-31 | $63.00 | $0.90 | x |
| 2019-12-31 | $55.99 | $0.90 | x |
| 2020-12-31 | $46.10 | $0.90 | x |
| 2021-12-31 | $37.43 | $0.90 | x |
| 2022-12-31 | $24.82 | $0.90 | x |
| 2023-12-31 | $0.77 | $0.90 | x |
| 2024-12-31 | $0.91 | $0.90 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Evolva Holding SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.83%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.14x
- Recent ROE (15.83%) is above the historical average (-123.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | -26.77% | 0.00% | 0.00x | 1.04x | $-48.13 Million |
| 2006 | -110.77% | -26513.74% | 0.00x | 1.28x | $-79.08 Million |
| 2007 | -88.08% | -35937.03% | 0.00x | 1.29x | $-65.83 Million |
| 2008 | -39.62% | -2040.98% | 0.01x | 2.03x | $-10.85 Million |
| 2009 | -14.22% | -50.77% | 0.20x | 1.37x | $-16.37 Million |
| 2010 | -44.88% | -125.07% | 0.25x | 1.45x | $-28.49 Million |
| 2011 | -30.89% | -202.64% | 0.10x | 1.47x | $-29.72 Million |
| 2012 | -26.13% | -228.19% | 0.08x | 1.48x | $-22.13 Million |
| 2013 | -19.49% | -180.70% | 0.08x | 1.30x | $-23.80 Million |
| 2014 | -12.33% | -230.02% | 0.04x | 1.23x | $-38.67 Million |
| 2015 | -15.82% | -339.28% | 0.04x | 1.15x | $-52.05 Million |
| 2016 | -21.02% | -411.19% | 0.04x | 1.16x | $-53.08 Million |
| 2017 | -17.66% | -569.26% | 0.03x | 1.09x | $-61.05 Million |
| 2018 | -15.05% | -327.03% | 0.04x | 1.10x | $-48.63 Million |
| 2019 | -12.54% | -186.61% | 0.06x | 1.11x | $-38.90 Million |
| 2020 | -20.59% | -396.10% | 0.05x | 1.15x | $-44.38 Million |
| 2021 | -31.32% | -417.76% | 0.06x | 1.19x | $-54.44 Million |
| 2022 | -40.82% | -279.08% | 0.12x | 1.23x | $-53.99 Million |
| 2023 | -1895.13% | -1114.95% | 0.96x | 1.77x | $-105.78 Million |
| 2024 | 15.83% | 0.00% | 0.00x | 1.14x | $384.37K |
Industry Comparison
This section compares Evolva Holding SA's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $177,595,389
- Average return on equity (ROE) among peers: -116.12%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Evolva Holding SA (ELVAF) | $6.60 Million | -26.77% | 0.14x | $4.82 Million |
| Aadi Bioscience Inc (AADI) | $17.44 Million | -122.74% | 0.21x | $17.03 Million |
| America Great Health (AAGH) | $-5.31 Million | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $274.16 Million | -147.88% | 8.55x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $54.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $4.67 Million | -803.57% | 14.26x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $1.23 Billion | 12.85% | 0.25x | $731.78 Million |
| Abeona Therapeutics Inc (ABEO) | $134.04 Million | -42.28% | 0.30x | $193.84 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $-18.59 Million | 0.00% | 0.00x | $102.67 Million |
| Abpro Holdings, Inc. (ABP) | $-14.95 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $179.13 Million | -57.56% | 0.19x | $345.85 Million |